Literature DB >> 16631452

The evolution of imaging in advanced prostate cancer.

Michael J Manyak1, Marcia Javitt, Pil S Kang, William R Kreuger, Erik S Storm.   

Abstract

Medical advances will be driven by the enhancement of imaging for diagnosis, refinement of treatment, and evaluation of treatment efficacy. The convergence of technology in materials science, biology, and the computer industry has greatly advanced diagnostic imaging. Precision in control of the spatial and temporal properties of light and its heterogeneous scattering properties have extended our capability for imaging. Refinements in radioimmunoscintigraphy for image acquisition, fusion of images, and outcome data now suggest use for image-guided therapy. Novel MRI agents appear to provide significant imaging capabilities to detect malignant lymph nodes. Future applications of optical coherence tomography, electron paramagnetic resonance imaging, nanotechnology, molecular imaging, and hyperspectral spectroscopy promise further refinements to image tissues for diagnosis.

Entities:  

Mesh:

Year:  2006        PMID: 16631452     DOI: 10.1016/j.ucl.2005.12.014

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  5 in total

Review 1.  Optimal cost-effective staging evaluations in prostate cancer.

Authors:  Gregory L Lacy; Douglas W Soderdahl; Javier Hernandez
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

2.  Role of optical spectroscopy using endogenous contrasts in clinical cancer diagnosis.

Authors:  Quan Liu
Journal:  World J Clin Oncol       Date:  2011-01-10

Review 3.  Current and evolving uses of optical coherence tomography in the genitourinary tract.

Authors:  Mohit Gupta; Li-Ming Su
Journal:  Curr Urol Rep       Date:  2015-03       Impact factor: 3.092

Review 4.  Nanotechnology in urology.

Authors:  Shihua Jin; Vinod Labhasetwar
Journal:  Urol Clin North Am       Date:  2009-05       Impact factor: 2.241

5.  N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer.

Authors:  Ronnie C Mease; Crystal L Dusich; Catherine A Foss; Hayden T Ravert; Robert F Dannals; Jurgen Seidel; Andrew Prideaux; James J Fox; George Sgouros; Alan P Kozikowski; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.